New LDL cholesterol target ahead?

03/4/2013 | Nature (free content)

For the first time in a decade, the U.S. National Heart, Lung and Blood Institute is expected to reconsider its clinical guidelines for LDL cholesterol. Statins have been shown to lower the risk of cardiovascular events, but it has not been proven that reducing LDL with other pharmaceuticals has an impact, some cardiologists say. "We can't just assume that modifying the risk factor is modifying risk," says Harlan Krumholz of Yale University.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC